ERBB2 and breast carcinoma: Previously, we showed that the in vivo treatment of HER2-overexpressing gefitinib-resistant JIMT-1 breast cancer xenografts with free HCQ and gefitinib (in combination) resulted in a 58% reduction in tumor volume compared to vehicle-treated controls [7].